Home – CDMO Solutions | Viral Vectors | Adenovirus

Adenovirus manufacturing expertise proven at scale

OXB is an experienced partner for adenovirus development and manufacturing, most famously demonstrated during the COVID-19 pandemic, when OXB manufactured over 100 million doses of the Oxford–AstraZeneca COVID-19 vaccine. As a quality and innovation-led CDMO, OXB now offers custom adenovirus development as well as tech transfer-in to its clients.

OXB’s adenovirus track record

0

million

COVID-19 vaccine doses manufactured

0E17

vg/mL

At 1,000L scale

0

months

To GMP release

Adenovirus technology and expertise

At OXB, our expertise spans chimpanzee adenovirus (ChAdOx1) and other adenoviral platforms, with capabilities ranging from cell line and process development through GMP production, analytics, fill/finish, and regulatory support. Our processes are built on deep in-house knowledge of vector biology and industrial bioprocessing, enabling rapid, reliable, and scalable production.

OXB-Adenovirus-technology-and-expertise-832x480px

Why choose OXB as your adenovirus CDMO?

Experienced partner for adenovirus development and manufacturing

OXB-Viral vectors-Other viral vectors-3-800x800px

Proven global delivery

OXB has manufactured adenoviral vectors at a scale few others can match, contributing to millions of doses supplied worldwide.

OXB-Why-choose-OXB-Flexible-end-to-end-CDMO-model-800x800px

Flexible end-to-end CDMO model

Streamlined development through proven platform processes minimizes risk, accelerates timelines, and cuts expenses.

OXB-CDMO-GMP-manufacturing-3-800x800px

Advanced GMP infrastructure

OXB has GMP facilities in the UK, Europe and USA to meet the geographical needs of our clients and ensure they benefit from cutting-edge technology and secure global supply chains.

Ways to work with us

There are multiple ways in which pharma, biotechs and start-ups work with us, depending on development phase, scale, and individual IP requirements.

White-hexagon

Platform project

For clients that are pre-clinical or early-clinical that wish to reach GMP at an accelerated rate with a proven process.

White-hexagon

Custom solution

For clients that are pre-clinical or early-clinical that require flexibility in the manufacture of their drug candidate.

White-hexagon

Tech-transfer

For clients in phase I, II, or III that need to transfer their manufacture to a CDMO for scale and/or long-term manufacture.

Flex-box-Ways-to-work-with-us-1-840x480px
Flex-box-Ways-to-work-with-us-2-840x480px
Flex-box-Ways-to-work-with-us-3-840x480px

Frequently asked questions

Can OXB support both clinical and commercial adenovirus manufacturing?
Does OXB offer GMP-grade adenovirus vector production?
What analytical testing and quality control does OXB offer for adenovirus vectors?
What advantages does OXB offer compared to other adenovirus CDMOs?